ArticleHaematologica2024

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.

Massimo Gentile et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.